Brexpiprazole

(Rexulti®)

Brexpiprazole

Drug updated on 11/10/2023

Dosage FormTablet (oral; 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg)
Drug ClassAtypical antipsychotics
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults
  • Treatment of schizophrenia in adults and pediatric patients ages 13 years and older.
  • Treatment of agitation associated with dementia due to Alzheimer’s disease

Product Monograph / Prescribing Information

Document TitleYearSource
Rexulti (brexpiprazole) Prescribing Information.2021FDA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Systematic literature review and network meta-analysis of lurasidone, brexpiprazole and cariprazine for schizophrenia.2023International Clinical Psychopharmacology
Comparative efficacy and safety of 4 atypical antipsychotics augmentation treatment for major depressive disorder in adults: A systematic review and network meta-analysis2023Medicine
Optimal dose of brexpiprazole for augmentation therapy of antidepressant-refractory depression: a systematic review and dose-effect meta-analysis.2022Psychiatry and Clinical Neurosciences
Efficacy and safety of adjunctive serotonin-dopamine activity modulators in major depression: a meta-analysis of randomized controlled trials. 2022Journal of Clinical Pharmacology
Augmentation strategies for treatment resistant major depression: a systematic review and network meta-analysis.2022Journal of Affective Disorders
Antipsychotic-induced weight gain: dose-response meta-analysis of randomized controlled trials.2022The Journal of Psychoses and Related Disorders
Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis.2022Psychological Medicine
Efficacy and acceptability of second-generation antipsychotics with antidepressants in unipolar depression augmentation: a systematic review and network meta-analysis2022Psychological medicine
Efficacy and safety of antipsychotic treatments for schizophrenia: a systematic review and network meta-analysis of randomized trials in Japan.2021Journal of Psychiatric Research
Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium2021Journal of psychopharmacology
Efficacy and safety of antipsychotic treatments for schizophrenia: A systematic review and network meta-analysis of randomized trials in Japan2021Journal of psychiatric research
Blonanserin patch vs. other antipsychotics for acute schizophrenia: a systematic review of double-blind, randomized, placebo-controlled, phase 3 trials in Japan.2020Pharmacopsychiatry
Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis.2020Psychopharmacology
Brexpiprazole as adjunctive treatment for major depressive disorder following treatment failure with at least one antidepressant in the current episode: a systematic review and meta-analysis.2019International Journal of Neuropsychopharmacology
Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.2019Lancet
Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis2019CNS drugs
Australian public assessment report for brexpiprazole.2018Australian Government: Department of Health
Assessment report: Rexulti.2018EMA
Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials.2018Neuropsychiatric Disease and Treatment
Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies2017Neuropsychiatric disease and treatment